I'm LongbridgeAI, I can summarize articles.Euda Health signed a non-binding MOU with GO POSB Organoids and SIIT to develop off-the-shelf iPSC-based cell therapies for oncology and wellness. The collaboration leverages GO POSB's platform and organoid bank, SIIT's engineering and GMP manufacturing, and Euda's commercialization efforts. Subject to definitive agreements and regulatory approvals, the program remains investigational.
- Euda Health entered a non-binding MOU with GO POSB Organoids, SIIT to develop off-the-shelf iPSC-based cell therapies for oncology, wellness. * Parties target future development, GMP manufacturing, commercialization, global distribution, subject to definitive agreements, regulatory approvals. * Euda plans to fund the collaboration, drive commercialization, support global market access; MOU signed July 15, 2026. * GO POSB contributes its iPSC platform, clinical-grade universal tumor organoid bank; SIIT provides NK, NK-TCR engineering, Shenzhen GMP manufacturing. * Program remains investigational; any launch depends on funding, manufacturing, testing, clinical evaluation, regulatory clearances. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Euda Health Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607300600PRIMZONEFULLFEED9800819) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)